These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. Doyle AJ; Stubbs MJ; Lester W; Thomas W; Westwood JP; Thomas M; Percy C; Prasannan N; Scully M Br J Haematol; 2022 Jul; 198(2):391-396. PubMed ID: 35430727 [TBL] [Abstract][Full Text] [Related]
7. Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator. Kwon HC; Kim MK; Song JJ; Park YB; Lee SW Yonsei Med J; 2020 Aug; 61(8):712-719. PubMed ID: 32734735 [TBL] [Abstract][Full Text] [Related]
8. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A; Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178 [TBL] [Abstract][Full Text] [Related]
9. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. Chen H; Fu A; Wang J; Wu T; Li Z; Tang J; Shen H; Zhu J; Li J; Zhu Q; Qing L J Int Med Res; 2017 Jun; 45(3):1253-1260. PubMed ID: 28639502 [TBL] [Abstract][Full Text] [Related]
11. [Successful rituximab treatment in an elderly patient with recurrent thrombotic thrombocytopenic purpura]. Matsubara E; Yamanouchi J; Hato T; Takeuchi K; Niiya T; Yasukawa M Rinsho Ketsueki; 2016 Jul; 57(7):869-72. PubMed ID: 27498731 [TBL] [Abstract][Full Text] [Related]
12. Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus. Shin SH; Kim JY; Kim SC; Kim JH J Dermatol; 2024 Aug; 51(8):1104-1107. PubMed ID: 38874429 [TBL] [Abstract][Full Text] [Related]
13. Comparison of low fixed dose versus standard-dose rituximab to treat thrombotic thrombocytopenic purpura in the acute phase and preemptively during remission. Reddy MS; Hofmann S; Shen YM; Nagalla S; Rambally S; Usmani A; Sarode R Transfus Apher Sci; 2020 Dec; 59(6):102885. PubMed ID: 32739120 [TBL] [Abstract][Full Text] [Related]
14. Safety of switching between rituximab biosimilars in onco-hematology. Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667 [TBL] [Abstract][Full Text] [Related]
17. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Doyle AJ; Stubbs MJ; Dutt T; Lester W; Thomas W; van Veen J; Hermans J; Cranfield T; Hill QA; Clark A; Bagot C; Austin S; Westwood JP; Thomas M; Scully M Blood; 2023 Jan; 141(3):285-294. PubMed ID: 36322971 [TBL] [Abstract][Full Text] [Related]
18. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature. Al-Husban N; Al-Kuran O J Med Case Rep; 2018 Jun; 12(1):147. PubMed ID: 29855343 [TBL] [Abstract][Full Text] [Related]